Brisbane-based medtech company Microbio is leveraging advanced manufacturing capabilities through a partnership with Queensland’s Advanced Robotics for Manufacturing (ARM) Hub to scale and globalise its rapid sepsis detection technology.
Microbio’s InfectID-BSI test can identify 26 sepsis-causing pathogens directly from blood samples in under three hours, ARM Hub said in a news release.
To support the international rollout of InfectID-BSI, Microbio required the capability to manage vast and complex clinical trial data across multiple countries.
ARM Hub said that beyond data handling, the company faced the broader challenge of evolving from a research-focused startup into a scalable, AI-driven diagnostic manufacturer.
Since 2023, ARM Hub has worked closely with Microbio to design and implement a smart, automated data system using Databricks’ AI Lakehouse platform.
This new digital infrastructure enables Microbio’s team – including non-technical staff – to analyse data and manage trials globally, supporting more efficient manufacturing and regulatory processes.
Phase one of the infrastructure was completed in May 2025 and will underpin Microbio’s submission to the US FDA for 810K clearance, expected in late 2026.
“Instead of exporting Australia’s medtech talent as raw IP for others to profit from, Microbio is proving how we can lead globally—by turning cutting-edge research into business nous through data-driven trials, continuous data-led service innovation, and a lean and productive workforce,” said Cori Stewart, CEO of ARM Hub.
Microbio has secured distribution deals across Asia and Europe, including an agreement with Palex Espana signed in May 2025.
It also received funding in December 2024 through ARM Hub and MTP Connect’s BASA Accelerator and additional matched support via ARM Hub’s Scaleup Manufacturing for Female Founders program.
